Hypothalamic nitric oxide in hypoglycemia detection and counterregulation: a two-edged sword by Fioramonti, Xavier et al.
Hypothalamic nitric oxide in hypoglycemia detection
and counterregulation: a two-edged sword
Xavier Fioramonti, Zhentao Song, Reema P. Vazirani, Annie Beuve, Vanessa
H. Routh
To cite this version:
Xavier Fioramonti, Zhentao Song, Reema P. Vazirani, Annie Beuve, Vanessa H. Routh.
Hypothalamic nitric oxide in hypoglycemia detection and counterregulation: a two-edged
sword. Antioxidants and Redox Signaling, Mary Ann Liebert, 2011, 14 (3), pp.505-517.
<10.1089/ars.2010.3331>. <hal-01137049>
HAL Id: hal-01137049
https://hal.archives-ouvertes.fr/hal-01137049
Submitted on 10 Oct 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
FORUM ARTICLE
Hypothalamic Nitric Oxide
in Hypoglycemia Detection and Counterregulation:
A Two-Edged Sword
Xavier Fioramonti, Zhentao Song, Reema P. Vazirani, Annie Beuve, and Vanessa H. Routh
Abstract
Hypoglycemia is the main complication for patients with type 1 diabetes mellitus receiving intensive insulin
therapy. In addition to the obvious deleterious effects of acute hypoglycemia on brain function, recurrent
episodes of hypoglycemia (RH) have an even more insidious effect. RH impairs the ability of the brain to detect
and initiate an appropriate counterregulatory response (CRR) to restore euglycemia in response to subsequent
hypoglycemia. Knowledge of mechanisms involved in hypoglycemia detection and counterregulation has sig-
nificantly improved over the past 20 years. Glucose sensitive neurons (GSNs) in the ventromedial hypothalamus
(VMH) may play a key role in the CRR. VMH nitric oxide (NO) production has recently been shown to be critical
for both the CRR and glucose sensing by glucose-inhibited neurons. Interestingly, downstream effects of NO
may also contribute to the impaired CRR after RH. In this review, we will discuss current literature regarding the
molecular mechanisms by which VMH GSNs sense glucose. Putative roles of GSNs in the detection and initi-
ation of the CRR will then be described. Finally, hypothetical mechanisms by which VMH NO production may
both facilitate and subsequently impair the CRR will be discussed. Antioxid. Redox Signal. 00, 000–000.
Introduction
According to the diabetes control and complicationstrial, the development of complications due to hyper-
glycemia (neuropathy, retinopathy, and nephropathy) in pa-
tients with type 1 diabetes mellitus (T1DM) is reduced but not
eliminated by partial glycemic control (1). Tight glycemic
control, which can be achieved by intensive insulin therapy,
significantly improves diabetic-related complications but is
limited by the induction of iatrogenic hypoglycemia. Most
people with T1DM but also those with advanced type 2 dia-
betes mellitus who require intensive insulin therapy experi-
ence hypoglycemia. As glucose is the principal fuel for the
brain, severe hypoglycemia often leads to seizure and=or
coma. A detailed discussion of the ramifications of hypogly-
cemia in diabetes is beyond the scope of this review and is
very well described by P.E. Cryer in the ‘‘The Barrier of Hy-
poglycemia in Diabetes’’ (22).
Hypoglycemia counterregulation and
hypoglycemia-associated autonomic failure
It is clear that maintaining a satisfactory range of blood
glucose is a fundamental concern of the brain since this organ
cannot synthesize glucose. Rather, the brain relies on a con-
stant supply of glucose coming from the bloodstream. Thus,
hypoglycemia is a profound threat to the brain. As a result,
hypoglycemia triggers a coordinated series of neuroendocrine
events that restore euglycemia. These events known as the
counterregulatory response (CRR) are initiated in sequence as
blood glucose levels fall (Fig. 1). As the blood glucose level
decreases to 80–85mg=dL, insulin secretion is inhibited.
When the blood glucose level reaches 65–70mg=dL, glucagon
secretion increases followed by increases in epinephrine and
then cortisol secretion (22, 46). The net result of the CRR is an
increase in liver and kidney glucose production and a de-
crease in muscle and fat glucose uptake, which ultimately
restore euglycemia (Fig. 1).
Unfortunately, CRR mechanisms become impaired as a
consequence of recurrent hypoglycemic episodes (recurrent
hypoglycemia, RH). This impairment is known as hypoglycemia-
associated autonomic failure (HAAF). During HAAF, in ad-
dition to CRR impairment, hypoglycemia awareness is also
altered. As a consequence, the glycemic threshold for CRR
initiation and hypoglycemia awareness shifts to lower glucose
levels. Themajor risk of HAAF is that blood glucose levels can
fall to dangerously low or lethal levels without detection.
Thus, the development of HAAF after RH is a major limiting
factor in the management of patients with T1DM as well as
patients with advanced type 2 diabetes mellitus who require
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intensive insulin therapy. Interestingly, HAAF can be re-
versed after 2–3 weeks of rigorous avoidance of insulin-
induced hypoglycemia (22). Although HAAF is a serious
health issue, the mechanisms by which it occurs, as well as
reverses, are not well understood.
In this review, we will discuss what is known regarding
central regulation of the CRR, and specifically the putative
roles of glucose-sensing neurons (GSNs) in the ventromedial
hypothalamus (VMH) in this response. We will focus on the
novel role played by hypothalamic nitric oxide (NO) in CRR
initiation and VMH glucose sensing. Finally, we will present
possible mechanisms by which VMH NO production could
also contribute to HAAF.
Central Nervous System Control of the CRR
Role of the VMH in the CRR
In animal studies, glucose sensors have been found both in
peripheral tissues (pancreatic b-cells, intestine, carotid body,
and hepatoportal vein) and in the central nervous system
(amygdala, septum, striatum, motor-cortex, and hindbrain)
(62), including the hypothalamus (15, 31, 68, 76). The respec-
tive roles of these peripheral and central glucose sensors in
hypoglycemia detection and the control of the CRRwill not be
discussed here. However, it is noteworthy that the relative
importance of the central versus peripheral glucose sensors in
the initiation of the CRR depends on the rate of blood glucose
level decline. In an elegant study, Donovan’s group has re-
cently shown that the hepatoportal glucose sensor dominates
when hypoglycemia develops slowly and is responsible for
over 90% of the sympathoadrenal response to hypoglycemia.
When hypoglycemia develops faster, brain glucose sensors
play a predominant role in the hypoglycemia detection and
CRR initiation (64). While there are numerous studies that
preferentially evaluate either peripheral or central glucose
sensors during hypoglycemia, less is known about how these
glucose sensors interact and coordinate the generation of the
CRR. A recent review by Watts and Donovan begins to ad-
dress this issue (77).
In the current review,wewill focus our attention on the role
played by the glucose sensors that exist in the VMH. It is
generally well accepted that the VMH plays a key regulatory
role in the control of the CRR. Electrical stimulation of the
VMH in a rodent model activates the sympathoadrenal sys-
tem in a manner similar to that seen during the CRR (72).
Chemical destruction of the VMH with ibotenic acid inhibits
the CRR to acute hypoglycemia (13). Local perfusion of the
VMH with 2-deoxyglucose (2-DG, a nonmetabolizable form
of glucose that mimics local hypoglycemia) stimulates the
production of CRR hormones, whereas local VMH perfusion
with glucose during systemic hypoglycemia inhibits the CRR
(11, 14).
It is important to note the VMH actually consists of two
different nuclei: the ventromedial (VMN) and the arcuate
(ARC) nuclei. Their respective role in the control of the CRR is
poorly understood. The VMN projects to autonomic outflow
areas of the spinal cord via a brainstem projection to the
periaqueductal gray and the reticular formation (24). Such
projections are consistent with a stimulation of sympatho-
adrenal responses seen during the initiation of the CRR. On
the other hand, the ARC may be more involved in the control
of food intake and energy expenditure [for review, see ref.
(66)]. In vivo studies of the VMH lack the specificity to dis-
tinguish between the ARC and the VMN. Since VMN pro-
jections appearmost likely to be involved in the CRR, we have
chosen to use VMN glucose sensors in our in vitro studies as
prototypes to understand the cellular basis of central regula-
tion of the CRR. This, however, does not exclude a role for
ARC or other central glucose sensors in CRR regulation.
The VMN glucose sensors
Hypothalamic neurons that modulate their electrical ac-
tivity in response to changes in extracellular glucose level
were first characterized in the 1960s (5, 57). These GSNs use
glucose, not only as fuel, but also as a signaling molecule that
FIG. 1. Neuroendocrine pathways involved in the CRR to
hypoglycemia. Decreased blood glucose is detected by cen-
tral (hypothalamus and hindbrain) and peripheral (pancreas,
hepatoportal vein, and carotid body) glucose sensors. To-
gether, these glucose sensors coordinate physiological re-
sponses that raise blood glucose levels. The initial response to
hypoglycemia involves activation of the ANS, inhibition of
insulin secretion, and stimulation of pituitary adrenocortico-
tropic hormone (ACTH) secretion. Activation of the auto-
nomic nervous system increases glucagon and epinephrine
secretion from the pancreas and adrenal medulla, respec-
tively. ACTH stimulates cortisol release from the adrenal
cortex. Increased glucagon, epinephrine, and cortisol together
with decreased insulin stimulate hepatic glucose production
and decrease adipose and muscle glucose uptake. The net
result of the neuroendocrine CRR to hypoglycemia is to in-
crease blood glucose levels and restore euglycemia. ANS,
autonomic nervous system; CRR, counterregulatory response.
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regulates their electrical activity. In most cerebral areas pro-
tected by the blood–brain barrier (including the VMN), brain
extracellular glucose level is about 30% of that found in blood.
Thus, the extracellular brain glucose level ranges from 0.16 to
4.5mM during peripheral hypoglycemia (2–3mM) or hyper-
glycemia (15mM), respectively. During euglycemia, brain
extracellular glucose concentrations are approximately 2mM
(63). In the VMN, two types of GSNs have been found that
respond directly to changes in extracellular glucose levels
within this physiological range: the glucose-excited (GE)
neurons and the glucose-inhibited (GI) neurons (68). GE
neurons decrease whereas GI neurons increase their electrical
activity as the glucose level decreases from 2.5 to 0.1mM (68).
Interestingly, VMN GE and GI neurons are exquisitely sen-
sitive to decreases in glucose below 2.5mM while remaining
relatively insensitive to glucose increases above this level (68).
This suggests that VMN GE and GI neurons are capable of
playing a role in the detection of hypoglycemia and initiation
of the CRR.
GE neurons. GE neurons exhibit a concentration-
dependent increase in activity as extracellular glucose con-
centration rises (Fig. 2) (20, 68, 76). The mechanisms by which
these neurons sense changes in glucose levels are fairly well
understood. It has been proposed that GE neurons use similar
glucose-sensing mechanisms as the pancreatic b-cell, which
secretes insulin in response to increased glucose levels. In the
b-cell, glucose is transported by the high-capacity glucose
transporter 2 (GLUT2) and phosphorylated by the hexokinase
IV isoform, glucokinase (GK). Glucose metabolism increases
the intracellular ATP=ADP ratio, which consequently closes
ATP-sensitive potassium channels (KATP channels). KATP
channel closure depolarizes the b-cell and leads to Caþþ en-
trance, which in turn stimulates the exocytosis of insulin-
containing vesicles. In the b-cell, GLUT2, GK, and KATP are
considered the key glucosensors responsible for glucose-
stimulated insulin secretion.
KATP channels, the pancreatic form of GK and GLUT2, are
found throughout the brain, including hypothalamic regions
involved in glucose sensing (6, 25, 27). Subunits of KATP
channels and GK are expressed and functional in VMH GE
neurons (41). Modulating the activity of KATP channels or GK
alters glucose sensitivity of VMH GE neurons (7, 40, 68). Less
is known regarding the involvement of GLUT2 in VMN GE
neurons glucose sensing. GLUT2 has been mainly found in
astrocytes but not in neurons (6). In addition, Kang et al.
showed that GLUT2 is only expressed in*20% of VMH GE
neurons (41). Other GLUTs such as GLUT3 and the insulin-
sensitive transporter GLUT4 are expressed in hypothalamic
neurons (4, 28, 41, 75). GLUT3 is expressed in 83% andGLUT4
in 57% of VMN GE neurons (41). Thus, whether a specific
GLUT confers glucose sensitivity has yet to be determined.
The question that remains to be answered is whether VMH
GE neurons play a role in the CRR to hypoglycemia. Altera-
tions in the glucose-sensing machinery of VMN GE neurons
are associatedwith CRR impairment, which is consistent with
a role of GE neurons in the CRR. For example, glucagon
production in response to insulin-induced hypoglycemia is
impaired in Kir6.2-deficient mice lacking both functional
KATP channels and VMH GE neurons (52). In addition, Sher-
win’s group showed that in vivo modulation of activity of
KATP channels with sulphonylureas alters the CRR. VMH
infusion of glibenclamide (KATP channel blocker) suppresses,
whereas diazoxide (KATP channel opener) amplifies, the CRR
during hypoglycemic clamp (29, 47). Levin and colleagues
showed that modulation of GK activity altered both the glu-
cose sensitivity of VMH GE neurons in vitro and the CRR in
vivo (26, 40, 43). These data suggest that VMH GE neurons,
through KATP channels and GK, play an important role in the
control of the CRR. However, KATP channel expression is
ubiquitous and is not specific to GE neurons. Thus, modula-
tion of KATP channel activity would alter the electrical activity
of other GSNs as well as non-GSNs. In contrast, GK expres-
sion seems relatively specific to VMH GSNs (41). However,
FIG. 2. Molecular mecha-
nisms by which VMN GE
sense glucose. Decreased
extracellular glucose leads to
decreased glycolytic flux and
decreases the ATP=AMP ratio.
Decreased intracellular ATP
level opens KATP channels that
hyperpolarize the cell leading
to decreased APF and NT re-
lease. APF, action potential
frequency; GE, glucose-excited;
KATP, ATP-sensitive K
þ; NT,
neurotransmitter; VMN, ven-
tromedial nucleus.
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GK has a very low glucose affinity (*10mM), which is well
above the brain glucose concentration range. Thus, the role
played by GK in hypoglycemia detection still remains con-
troversial.
Further evidence from our laboratory suggests that GE
neurons are involved in the CRR. We found that the response
of VMNGE neurons to decreased glucose is attenuated under
conditions where the CRR is impaired. Our laboratory and
others have shown that the CRR is impaired after three con-
secutive daily episodes of insulin-induced hypoglycemia in
rats (RH model) (23, 70). Using this model, we found that RH
impairs the response of VMN GE neurons to decreased glu-
cose (Fig. 3). In control animals, VMN GE neurons decreased
their input resistance, membrane potential, and action po-
tential frequency (APF) in response to glucose decreases from
2.5 to 0.5 or 0.1mM. However, in RH animals, VMN GE
neurons only decrease their input resistance, membrane po-
tential, and APF when glucose is lowered to 0.1 but not
0.5mM (Fig. 3). Thus, the threshold glucose level at which GE
neurons become inhibited is lowered after RH. These results
are consistent with a role for VMN GE neurons in the CRR.
However, more work is necessary to further confirm a causal
role between impaired VMN GE neuronal glucose sensing
and impaired CRR.
GI neurons. GI neurons increase their electrical activity as
extracellular glucose concentration decreases (Fig. 4) (68).
Recently, significant progress has been made in the elucida-
tion of the VMH GI neuronal glucose-sensing mechanisms.
GK, AMP-activated kinase (AMPK), neuronal NO synthase
(nNOS), and the cystic fibrosis transmembrane regulator
(CFTR) are all critical for glucose sensing. The specific GLUT
is still uncertain. Among VMN GI neurons, 22% express
GLUT2, 96% express GLUT3, and 63% express GLUT4 (41).
Thus, as for GE neurons, a specific GLUT has yet to be im-
plicated. GK is expressed in about 50% of VMH GI neurons
(41). Modulation of GK activity alters the glucose sensitivity
of VMHGI neurons (26, 40). These data suggest that, as in GE
neurons, GK is an important regulator of glucose sensing in at
least some VMN GI populations.
In contrast to GE neurons, AMPK is a key component of
glucose sensing in GI neurons (16, 21, 56). Alterations in
AMPK activity are associated with changes in glucose sensi-
tivity of VMH GI neurons. Decreased glucose decreases the
ATP=AMP ratio and increases VMH AMPK activity (56).
Activation of AMPK activity mimics while inhibition of
AMPK activity inhibits the response of VMH GI neurons to
decreased glucose (54, 56). We have recently shown that
nNOS is a downstream mediator of AMPK effects in GI
neurons. It is well established that AMPK phosphorylates and
activates nNOS inmany tissues, including the brain (2, 44, 80).
We have found this to be true in VMNGI neurons as well (16,
56). Further, VMH GI neurons produce NO in response to
decreased glucose (16). NO production is a fundamental step
in VMH GI neuronal glucose sensing. nNOS-deficient mice
lack VMH GI neurons (32). In addition, nNOS inhibition im-
pairs VMH GI neuronal responses to decreased glucose as
well as AMPK activation (56).
The downstream effects of NO on the glucose response of
VMN GI neurons are mediated through its receptor, soluble
guanylyl cyclase (sGC), which is found in the majority of
VMH neurons (16). When activated by NO, sGC increases
cyclic GMP (cGMP) levels, leading to depolarization of VMN
GI neurons. Interestingly, the NO-sGC-cGMP pathway is not
only downstream of AMPK but also provides a necessary
amplification of AMPK activity in VMNGI neurons. Our data
FIG. 3. The response of
VMN GE neurons to de-
creased glucose is impaired
after RH. Continuous whole
cell current clamp recordings
of VMN GE neurons in brain
slices from control rats (sa-
line-injected; A) or animals
injected daily for 3 consecu-
tive days with insulin subcu-
taneously (RH protocol; B).
(A) Decreased extracellular
glucose from 2.5 to 0.1mM
(top trace) or from 2.5 to
0.5mM (bottom trace) de-
creased membrane potential,
APF, and input resistance in
this VMN GE neuron from a
control rat in a concentration-
dependent manner. (B) In
contrast, membrane poten-
tial, APF, and input resis-
tance were only reduced in
response to decreased glu-
cose from 2.5 to 0.1mM (top trace) but not to decreased glucose from 2.5 to 0.5mM (bottom trace) in this VMNGEneuron from a
rat exposed to RH. Changes in glucose concentration ([Glc]) are shown below each trace. Resting membrane potential (Vm) is
represented by the dotted line and mentioned on the right of each trace. The downward deflections represent the membrane
voltage response to a constant hyperpolarizing pulse (20pA) and were used to calculate input resistance. RH, recurrent
hypoglycemia.
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indicate that AMPK inhibition prevents the cell permeable
analog of cGMP, 8-Br-cGMP, from depolarizing GI neurons.
Thus, as in skeletal muscle (44) and endothelial cells (80) an
AMPK-NO-AMPK signaling loop links changes in intracel-
lular energy availability to physiological responses.
KATP channels are expressed and functional in VMH GI as
well as GE neurons (41, 69). However, in GI neurons increased
electrical activity in response to decreased glucose is corre-
lated with the closure of a chloride conductance (30, 68). The
CFTR is believed to be the chloride channel responsible for the
electrical activity changes in GI neurons. The CFTR is ex-
pressed in several brain regions, including the hypothalamus
(55). We have recently shown that CFTR phosphorylation is
regulated by AMPK in the VMH (56). Moreover, the CFTR
modulator gemfibrozil inhibits VMH GI neurons response to
decreased glucose (30). The CFTR channel is amember of ATP
binding cassette and possesses sulphonylurea-binding sub-
units (SUR) as do KATP channels (60). Thus, it is important to
note that in vivo studies using sulphonylureas do not target
GE neurons specifically through modulation of KATP channel
activity since GI neurons may also be affected as a result of
interactions with the sulfonylurea subunit of either KATP or
CFTR channels. The hypothetical mechanism for glucose
sensing of VMNGI neurons as indicated by our data is shown
in Figure 4.
Like GE neurons, the fact that VMN GI neurons are par-
ticularly sensitive to glucose deficit makes themwell suited to
play a role in hypoglycemia detection and counterregulation.
This hypothesis is supported by that fact that components of
VMN GI neuronal glucose-sensing machinery found to be
activated by decreased glucose in vitro are also activated in
vivo. That is, VMH AMPK activity is increased in response to
insulin-induced hypoglycemia (34) and to cerebral glucopenia
(3). VMHNOS activity is also increased in response to insulin-
induced hypoglycemia. In addition, manipulating VMN GI
neuronal glucose-sensing machinery in vivo alters the CRR.
For example, modulation of VMHGK activity affects the CRR
(43). Moreover, VMHAMPK inhibition attenuates the CRR to
acute hypoglycemia (34, 50). In contrast, stimulating VMH
AMPK activity amplifies the CRR to acute hypoglycemia and
restores the impaired CRR after RH (48, 49). Interestingly,
while the AMPK activator AICAR stimulates VMH GI neu-
rons in vitro, VMH AICAR infusion during euglycemia does
not initiate the CRR (48). This is consistent with the idea that
multiple glucose sensors are necessary to coordinate the ini-
tiation of the CRR.
The hypothesis that VMN GI neurons play a role in the
control of the CRR is further supported by numerous studies,
indicating that VMNGI neuronal glucose sensitivity is altered
under conditions where the CRR is impaired. First, the re-
sponse of VMN GI neurons to decreased glucose is reduced
after RHwhen the CRR is impaired (70). Second, alterations in
VMH fuel source availability and=or utilization during hy-
poglycemia causes CRR impairment and reduces the response
of VMN GI neurons to decreased glucose. Like glucose, other
energy sources (e.g., lactate and ketone bodies) enter the brain
and support energy metabolism during glucose deficiency.
VMH lactate infusion inhibits the CRR during hypoglycemia
(12). Similarly, we found that increased extracellular lactate
levels attenuated the increase in APF of VMN GI neurons as
glucose decreased from 2.5 to 0.1mM (69). Thus, lactate
supplementation reduces the response of VMNGI neurons to
glucose deficit. Third, activation of the hypothalamic-pituitary-
adrenal axis impairs the CRR to subsequent hypoglycemia
and reduces VMNGI neuronal response to decreased glucose.
Systemic perfusion of corticotrophin-releasing factor or VMH
infusion of the endogenous corticotrophin-releasing factor
receptor 2 agonist urocortin inhibits the CRR in vivo (51). Si-
milarly, we found that urocortin decreases VMN GI neuronal
response to decreased glucose in vitro (51). Finally, our recent
FIG. 4. Molecular mecha-
nisms by which VMN GI
neurons sense glucose. De-
creased extracellular glucose
leads to decreased glyco-
lytic flux and increases the
AMP=ATP ratio ((1)–(3)). In-
creasedAMP levels activate the
AMPK ((4)). AMPK activation
phosphorylates and activates
nNOS increasing NO produc-
tion. NO binds to its receptor
sGC, which amplifies AMPK
activation ((5)). This amplifica-
tion of AMPK activity closes
the CFTR chloride channel
((6)). CFTR closure depolarizes
the GI neuron, leading to in-
creased APF and NT release.
AMPK, AMP-activated kinase;
CFTR, cystic fibrosis trans-
membrane regulator; GI,
glucose-inhibited; nNOS, neu-
ronal nitric oxide synthase;
sGC, soluble guanylate cyclase.
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data showing that VMH NO signaling is crucial for both the
full generation of the CRR in vivo and the ability of VMN GI
neurons to sense glucose in vitro provide a further support for
the hypothesis that VMN GI neurons play a key role in hy-
poglycemia detection and the initiation of the CRR (32). For
the remainder of this reviewwewill focus on the putative role
of NO signaling in central glucose sensing and the develop-
ment of HAAF.
The Role of NO in the CRR
NO is critical for activation of the CRR
As mentioned previously, decreased glucose activates
nNOS and increases NO production in VMHGI neurons (16).
Using in vitro and in vivo strategies, we recently confirmed
that nNOS-derived NO is produced in the VMH during hy-
poglycemia. Insulin-induced hypoglycemia increases VMH
constitutive NOS (nNOSþ endothelial [e] NOS) activity. In-
creased NOS activity during hypoglycemia is associated with
phosphorylation of the nNOS but not endothelial NOS
(eNOS) isoform. Moreover, we found that decreased glucose
levels in vitro increase extracellular NO release using electro-
chemical detection of NO production. Next, we established
that hypothalamic NO production is necessary for the full
generation of the CRR. Plasma epinephrine production is
impaired during a hyperinsulinemic=hypoglycemic clamp in
animals injected in the VMH with a nonselective NOS inhib-
itor. Additionally, nNOS-deficient mice have an impaired
CRR and lack VMN GI neurons (32). To strengthen our hy-
pothesis that hypothalamicNOproduction is a critical step for
the full generation of the CRR, we measured hypothalamic
NOS activity in response to insulin-induced hypoglycemia
after RH. Constitutive NOS activity is increased in response to
insulin-induced hypoglycemia in naive animals injected with
saline daily for 3 consecutive days. In contrast, no increase in
constitutive NOS activity was detected in RH animals (in-
jected with insulin daily for 3 consecutive days) in response to
a subsequent episode of insulin-induced hypoglycemia (Fig.
5). This shows that increased NOS activity in response to in-
sulin-induced hypoglycemia is impaired after RH. These data
support the idea that VMH NO production is an important
component of the central response to hypoglycemia and ini-
tiation of the CRR. Determination of the mechanisms leading
to impaired NOS activity after RH may lead to the develop-
ment of new therapeutic strategies to prevent the develop-
ment of HAAF.
Potential functions of hypothalamic NO
during hypoglycemia
NO, as a gas, diffuses freely across cell membranes, pro-
viding the opportunity to affect adjacent cells. The NO re-
ceptor sGC is distributed widely in the brain, and is present in
virtually all VMH neurons (16, 33). Thus, NO produced by
VMH GI neurons could modulate the activity of surrounding
VMH glucose sensing and non-GSNs or even glia or neigh-
boring capillaries. The consequences of such effects of NO are
discussed in the following sections.
NO and blood flow. In peripheral tissues, one of the main
physiological functions of NO is related to the vascular sys-
tem. It is well established that NO produced by endothelial
cells through the eNOS isoform induces the relaxation of
neighboring smooth muscle cells. This leads to vasodilatation
FIG. 5. RH impairs insulin-induced in-
creased NOS activity. (A) Experimental
protocol of RH. (B) Ventral hypothalamic
constitutive (e=nNOS) or iNOS NOS ac-
tivity measured 60min postinjection from
rats injected subcutaneously with NaCl
(saline) or insulin (4U=kg) on the 4th day
after 3 consecutive days of saline (SH) or
insulin (RH) treatment. *p< 0.05 versus
saline group (one-way ANOVA). iNOS,
inducible NOS; SH, single hypoglycemia.
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and increased blood flow (53). Human and animal studies
showed that insulin-induced hypoglycemia is associated with
increased cerebral blood flow in different brain areas, including
the hypothalamus (42, 58). Hypoglycemia-induced increases in
cerebral blood flow could increase nutrient availability to brain
cells during energy deficit. Insulin-induced hypoglycemia does
not increase eNOS activity (32). However, NO produced by
VMH GI neurons via the nNOS isoform could diffuse to adja-
cent smooth muscle cells and increase blood flow locally. The
role of NO on the control of brain blood flow during hypo-
glycemia remains controversial. Horinaka et al. showed that
hypoglycemia-induced increased blood flowwas not inhibited
by peripheral administration of a nonselective NOS inhibitor
(37). Nevertheless, concerns have been raised regarding the
ability of NOS inhibitors administered peripherally to cross the
blood–brain barrier and enter the brain in adult rats (9, 19).
Further in vivo studies using local inhibition of NOS activity
during hypoglycemia are required to determine whether
hypothalamic NO production is involved in hypoglycemia-
related vasorelaxation.
NO and nutrient supply. Studies performed by Bolanos’
group suggest that NO increases energy supply during en-
ergy deficit (Fig. 6). NO increases GLUT1 and GLUT3 ex-
pression in astrocytes and neurons, respectively (17). In
primary cortical cultures NO increases glycolytic flux in as-
trocytes (2, 10). Bolanos and colleagues proposed that NO
impairsmitochondrial respiration via cytochrome c inhibition,
which initially decreases the rate of ATP formation. The
resulting increase in the AMP=ATP ratio increases AMPK
activity. AMPK phosphorylates and activates 6-phosphofructo-
2-kinase. 6-Phosphofructo-2-kinase increases the formation of
fructose-2,6-bisphosphate from fructose-6-phosphate. Fruc-
tose-2-6-bisphosphate is the most potent activator of the rate
limiting enzyme in glycolysis, phosphofructo-1-kinase. Thus,
increased fructose-2-6-bisphosphate increases the rate of gly-
colysis, leading to ATP and pyruvate formation. Because
mitochondrial respiration is inhibited, pyruvate is then
transformed to lactate by lactate dehydrogenase rather than
metabolized through the Krebs cycle. Increased glycolytic
ATP level compensates for the energy deficit in astrocytes (9,
10) (Fig. 6). Lactate cannot be used by astrocytes as a source of
ATP under anaerobic conditions but may be transported to
adjacent neurons to fulfill their energy needs during hypo-
glycemia (see below). Astrocytes are also known to store
energy as glycogen. Glycogen stores provide substrates for
FIG. 6. Hypothetical role of NO production by VMN GI neurons in the astrocyte-neuron lactate shuttle. Decreased
extracellular glucose decreases GI neuronal intracellular ATP=AMP ratio and increases NO production through an AMPK-
dependent mechanism. Full AMPK activation closes CFTR channels and increases GI neurons APF. Decreased extracellular
glucose also decreases ATP=AMP ratio in GE neurons. Decreased ATP opens KATP channels and decreases GE neurons
membrane potential and APF. NO produced by VMN GI neurons could diffuse to adjacent astrocytes and inhibit mito-
chondrial Cyt c and consequently mitochondrial respiration. Decreased mitochondrial respiration decreases astrocytic ATP
levels, leading to AMPK activation. AMPK stimulates F-2,6-P formation via activation of PFK2. Increased F-2,6-P activates
PFK1, which increases formation of F-1,6-P and consequently increases glycolytic flux. Increased glycolytic rate increases
formation of anaerobic ATP and pyruvate. Pyruvate is converted lactate via LDH. Lactate may be transported to adjacent GI
and GE neurons viaMCT. In GI and GE neurons, lactate would increase intracellular ATP level, thus decreasing the response
of GI and GE neurons to subsequent glucose decreases. Cyt c, cytochrome c; F-1,6-P, fructose-1,6-bisphosphate; F-2,6-P,
fructose-2,6-bisphosphate; LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; PFK, phospho-fructo-kinase.
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glycolysis, leading to a further increase in ATP and lactate in
response to NO. Thus, NO produced by GI neurons may re-
store energy deficit in astrocytes during hypoglycemia by
increasing glycolytic ATP.
In neurons, however, because of low expression of 6-
phosphofructo-2-kinase, decreased ATP levels resulting from
NO-dependent cytochrome c inhibition do not enhance the
glycolytic production of ATP as seen in astrocytes (2, 9, 10).
Thus, the ATP deficit could lead to energy crisis and neuronal
death. However, Magistretti’s group has proposed that as-
trocytes have the ability to fuel neurons through an astrocyte-
neuron coupling pathway involving lactate transport. They
called this model the ‘‘astrocyte-neuron lactate shuttle’’ (45,
59). The astrocyte-neuron lactate shuttle model states that
during increased neuronal activity, the decrease in neuronal
energy level would be compensated by astrocytic lactate
production from glycogen stores and=or circulating glucose.
Lactate produced by astrocyte could be transported to adja-
cent neurons via monocarboxylic acid transporters and fulfill
their energy demands. Combining Bolanos’ and Magistretti’s
models leads to the hypothesis that NO produced by VMHGI
neurons during insulin-induced hypoglycemia increases lac-
tate production by neighboring astrocytes to fuel surrounding
glucose- or nonglucose-sensitive neurons via the astrocyte-
neuron lactate shuttle (Fig. 6). In support of this hypothesis,
monocarboxylic acid transporter 1 expression is increased
during hypoglycemia (74). However, no one has been able to
actually measure increased extracellular lactate during hy-
poglycemia. One possibility is that lactate is taken up by
neurons as fast as it is released from astrocytes. Thus, in-
creased extracellular lactate concentration during hypogly-
cemia would not be detectable. The other possibility, of
course, is that the astrocyte-neuron lactate shuttle hypothesis
is not valid in the hypothalamus during hypoglycemia. More
work is required to determine whether NO-stimulated lac-
tate production by astrocytes fuels neurons during insulin-
induced hypoglycemia.
NO and GE neurons. We found that VMN GE neurons
are fully functional in nNOS knockout mice. However, NO
produced by GI neurons could diffuse to adjacent GE neurons
and affect their glucose sensitivity. As discussed above, NO
inhibits the mitochondrial cytochrome c and decreases mito-
chondrial respiration and ATP formation. Consequently,
VMHGI neuronal NOproduction could further decrease ATP
level in GE neurons during decreased extracellular glucose.
Thus, the response of VMH GE neurons to decreased glucose
would be greater in the presence of surrounding NO pro-
ducing GI neurons. On the other hand, lactate produced by
astrocytes in response to GI neuronal NO production could
provide an energy source to GE neurons masking glucose
deficit. In this case, NO produced by GI neurons could de-
crease the response of VMH GE neurons to subsequent glu-
cose decrease. This hypothesis is discussed more in detail in
the next section. Further investigation is needed to determine
whether NO produced by GI neurons influences the glucose
sensitivity of GSNs.
To summarize, there are several putative functions for NO
produced by VMH GI neurons in the control of energy ho-
meostasis in addition to its role in GI neurons glucose sensing.
VMH NO production in GI neurons could participate in in-
creased blood flow locally during hypoglycemia. NO pro-
duction in GI neurons could also stimulate glycolysis in
astrocytes and increase neuronal fuel supplies as a result of
the astrocyte-neuron lactate shuttle. Finally, VMH NO pro-
duction during insulin-induced hypoglycemia could modu-
late glucose sensitivity of VMH GE neurons.
Involvement of hypothalamic NO in the CRR
impairment after RH
As mentioned in the Introduction, the CRR becomes im-
paired after recurrent episodes of insulin-induced hypogly-
cemia. While the mechanisms involved in the initiation of the
CRR are fairly well understood, mechanisms involved in its
impairment after RH are not. Our data show that VMH NO
production is required for full generation of the CRR and
glucose sensing in GI neurons. In the last part of this review
we will introduce the hypothesis that VMH NO production
also plays a role in the CRR impairment to subsequent hy-
poglycemia after RH.
NO and lactate. We hypothesized above that VMH NO
production increases astrocytic lactate production and trans-
port to surrounding neurons through an astrocyte-neuron
lactate shuttle. VMH infusion of lactate impairs the CRR
during hypoglycemic clamp (12). Moreover, increased extra-
cellular lactate concentration impairs the ability of VMN GI
and GE neurons to respond to decreased glucose (69). The
glucose-sensing machinery of both GI and GE neurons in-
volves changes in intracellular ATP level. In GI neurons, de-
creased ATP=AMP resulting from decreased extracellular
glucose activates AMPK, leading to CFTR channel closure
and depolarization. In GE neurons, decreased intracellular
ATP directly opens KATP channels, leading to hyperpolar-
ization. Increased extracellular lactate concentration may
raise neuronal ATP levels. Thus, increased lactate concentra-
tion would mask the effect of decreased glucose on the in-
tracellular ATP level (Fig. 6). Enhancing astrocytic production
of lactate to GSNs is therefore one mechanism by which NO
production during hypoglycemia could decrease the sensi-
tivity of GSNs to subsequent hypoglycemia and impair the
CRR. This phenomenon could be exacerbated by the fact that
hypothalamic glycogen content might be increased after RH
as described by Alquier and colleagues (3). These data are,
however, controversial since Herzog and colleagues found
no difference in hypothalamic glycogen level after acute or
RH (35). The difference between these two studies may be
due to the different RH models used (3 consecutive days of
intracerebro-ventricular 2-Deoxy-d-glucose [ICV 2-DG] in-
jection inAlquier et al. vs. 3 consecutive days of insulin-induced
hypoglycemia in Herzog et al.). Thus, while the hypothesis that
VMH NO production triggers an increase in the astrocyte-
neuron lactate shuttle which could participate in development
of HAAF after RH is intriguing, further investigation is needed
to resolve these controversies.
NO and reactive oxygen species. NO may also play a
role in the development of HAAF through the production of
reactive oxygen species (ROS) (Fig. 7). ROS production in
response to hypoglycemia is believed to occur in many brain
regions, including the hypothalamus. Insulin-induced hypo-
glycemia increases the level of lipid peroxidation and DNA
fragmentation while decreasing the level of reduced gluta-
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thione in rats (67). In addition, Leloup and Penicaud (CSGA,
Dijon, France) evaluated ROS production in the VMH of rats
injected with saline or insulin (4U=kg, subcutaneously) by
measuring the fluorescence of the ROS-sensitive probe
H2DCFDA (5,6-chloromethyl-2
0,70-dichlorodihydrofluorescein
diacetate acetyl ester). They found that H2DCFDA fluores-
cence was significantly increased by *50% in the VMH of
insulin-treated animals compared with saline controls (per-
sonal communication). These results provide further support
that ROS are produced in the VMH in response to insulin
hypoglycemia.
The mechanisms and cell types responsible for VMH ROS
production during hypoglycemia are unknown. One hy-
pothesis is that ROS formation is mediated by increased NO
production. As mentioned earlier, NO inhibits cytochrome c
and blocks mitochondrial respiration. A consequence of mi-
tochondrial respiration inhibition is the production of the
superoxide anion O2
 (18) (Fig. 7). Since VMH GI neurons
produce NO during insulin-induced hypoglycemia, one
might hypothesize that these GI neurons are the source of
ROS production. However, since NO can diffuse across cell
membranes it is also possible that NO triggers ROS produc-
tion in other cell types as well.
The effects of ROS on CRR impairment after RH are purely
speculative at this time. However, increased NO and ROS
production can alter protein function, which could lead to
FIG. 8. Hypothetical mechanisms by which NO production by VMN GI neurons modulates the CRR to hypoglycemia.
A decreased blood glucose level decreases the intracellular ATP level and stimulates NO production in VMN GI neurons
through an AMPK-dependent mechanism, leading to increased APF. In VMNGE neurons, decreased blood glucose decreases
the intracellular ATP level, leading to KATP opening and decreased APF. In addition to its role in GI neuronal glucose sensing
and CRR initiation, NO produced by GI neurons could diffuse to adjacent cells, and (1) modulate GE neurons glucose
sensitivity, (2) increase local blood flow, and=or (3) increase glycolytic flux in surrounding astrocytes. Increased astrocytic
glycolysis would increase lactate production and transport to surrounding GI andGE neurons altering their glucose sensitivity.
Finally ((4)), interaction between NO and ROS production could increase the level of protein nitration and=or S-nitrosylation
and affect the CRR to subsequent hypoglycemia. ROS, reactive oxygen species.
FIG. 7. Role of NO in protein posttranslational modifica-
tion. Increased NO production can alter protein structure and
ultimately function by nitration ((1)) and=or S-nitrosylation ((2),
(3)). (1) NO can inhibit mitochondrial cytochrome c and stim-
ulate generation of anion superoxide (O2
). Interaction be-
tween NO and O2
 forms peroxynitrite (ONOO). ONOO
can reactwith a free Tyr on proteins to formnitrated Tyr though
a reaction called tyrosine nitration. (2) ONOO can also react
with another molecule of NO to form dinitrogen trioxide
(N2O3). N2O3 can interact with free Cys thiols on proteins to
form S-nitro-thiol groups in a reaction called S-nitrosylation. (3)
In an oxidative environment, increased NO level can also in-
crease formation of GSNO and=or reactive NO (NO). GSNO
and NO can also interact with free Cys to induce S-nitrosyla-
tion. Cys, cysteine; GSNO, nitroso-glutathione; Tyr, tyrosine.
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CRR impairment (Fig. 7). NO and superoxide readily combine
to form peroxynitrite (ONOO) (8). Peroxynitrite can modify
protein structure in several ways, including the nonenzymatic
reactions tyrosine nitration and S-nitrosylation. Tyrosine ni-
tration consists in the addition of a nitro group (NO2) to
exposed tyrosine residue (38). In contrast, S-nitrosylation is
a reaction that results in the addition of an NO moiety to the
free thiol of a cysteine (Cys-SH) to form an S-nitroso-thiol
(Cys-S-NO) (36, 71). Peroxynitrite can also react with another
molecule of NO to form dinitrogen trioxide (N2O3), which
increases the level of S-nitrosylation. In an oxidative envi-
ronment, increased NO levels can also increase formation of
nitroso-glutathione (GSNO) and=or reactive NO (nitrosium
ion, NO), both of which can react with free cysteine thiols on
proteins, leading to increased S-nitrosylation (Fig. 7). A large
number of peripheral and central proteins are targets of
S-nitrosylation (39). Protein S-nitrosylation may be involved
in the control of glucose homeostasis since proteins involved
in glucose sensing are known targets of S-nitrosylation,
including GK (61), nNOS (78), sGC (65), and CFTR (79). For
instance, S-nitrosylation decreases NOS activity (78) and the
sensitivity of sGC for NO (65). In both cases, S-nitrosylation of
nNOS or sGCwould decrease NO signaling. Since VMHNO-
signaling is important for the generation of the CRR, inhibi-
tion of VMH NO-signaling by S-nitrosylation could lead to
CRR impairment to subsequent hypoglycemia and develop-
ment of HAAF. It is worth noting that this hypothesis is
consistent with our results showing that RH reduces NOS
activity andwith the results of Leloup and Penicaud (personal
communication) showing that hypoglycemia increases VMH
ROS levels. However, the hypothetical role of protein nitra-
tion and=or S-nitrosylation in the development of HAAF
remains to be determined.
Another hypothetical consequence of NO and ROS pro-
duction is induction of cell apoptosis. Prolonged or repetitive
concomitant NO and ROS production induces neuronal ap-
optosis. In support of this, one episode of severe hypoglyce-
mia is sufficient to increase the number of apoptotic cells in the
hypothalamus (73). The implication of apoptosis in the de-
velopment of HAAF is yet another hypothesis that requires
further evaluation
Conclusion
Our knowledge regarding mechanisms involved in the
brain detection of hypoglycemia and the initiation the CRR
has significantly evolved over the past 20 years (Fig. 8). A
growing body of evidence supports a role for VMHGI andGE
neurons in the regulation of the CRR. Further, the mecha-
nisms by which they sense glucose are fairly well character-
ized with the notable exception of GLUT isoform involved.
Work from our laboratory and others suggests that GK, and
the KATP channel in GE neurons and AMPK in GI neurons are
necessary for both glucose sensing and the CRR.
In the last few years, our laboratory has discovered the
involvement of a new and important key determinant of
glucose sensing in GI neurons and hypoglycemia counter-
regulation: NO. We found that (a) VMH GI neurons produce
NO in response to decreased glucose; (b) production of NO by
VMH GI neurons is required for glucose sensitivity in vitro,
and (c) VMHNO production is important in the regulation of
the CRR in vivo.
However, less is known regarding the mechanisms in-
volved in CRR impairment after RH. As discussed in this
review, we hypothesize that while NO is critical for central
glucose sensing, NO may also participate in the development
of HAAF. VMH NO production could (a) increase energy
supply to GSNs and decrease their glucose sensitivity via
increasing local blood flow or stimulating the astrocyte-
neuron lactate shuttle or (b) increase ROS production during
hypoglycemia and lead to alterations in glucose-sensing ma-
chinery and=or neuronal apoptosis (Fig. 8).
VMH NO production by GI neurons appears to be a nec-
essary component of hypoglycemia detection and counter-
regulation. However, overproduction and=or a coproduction
with ROS may impair the CRR and play a role in the devel-
opment of HAAF. Determining whether and how VMH NO
and ROS signaling are involved in the development of HAAF
will enable us to safely wield the powerful two-edged sword:
NO. In turn, such knowledge will provide new therapeutic
targets to reduce the risks of hypoglycemia in patients with
T1DM.
Acknowledgments
Authors would like to thank Dr. Thierry Alquier for helpful
discussions and critical reading of the article. This work was
supported inpart by researchawards from the JuvenileDiabetes
Research Foundation (V.H.R.), the National Health Institute
(2RO1DK55619 and 1RO1DK81358; V.H.R.), and a Juvenile
Diabetes Research Foundation postdoctoral award (X.F.).
References
1. The effect of intensive treatment of diabetes on the devel-
opment and progression of long-term complications in
insulin-dependent diabetes mellitus. The Diabetes Control
and Complications Trial Research Group. N Eng J Med 329:
977–986, 1993.
2. Almeida A, Moncada S, and Bolanos JP. Nitric oxide switches
on glycolysis through the AMP protein kinase and 6-phos-
phofructo-2-kinase pathway. Nat Cell Biol 6: 45–51, 2004.
3. Alquier T, Kawashima J, Tsuji Y, and Kahn BB. Role of hy-
pothalamic Amp kinase in the impaired counterregulatory
response induced by repetitive neuroglucopenia. Endocrino-
logy 148:1367–1375, 2006.
4. Alquier T, Leloup C, Arnaud E, Magnan C, and Penicaud L.
Altered Glut4 mRNA levels in specific brain areas of hyper-
glycemic- hyperinsulinemic rats.Neurosci Lett 308: 75–78, 2001.
5. Anand BK, Chhina GS, Sharma KN, Dua S, and Singh B.
Activity of single neurons in the hypothalamic feeding
centers: effect of glucose. Am J Physiol 207: 1146–1154, 1964.
6. Arluison M, Quignon M, Thorens B, Leloup C, and Penicaud
L. Immunocytochemical localization of the glucose trans-
porter 2 (GLUT2) in the adult rat brain. II. Electron micro-
scopic study. J Chem Neuroanat 28: 137–146, 2004.
7. Ashford ML, Boden PR, and Treherne JM. Glucose-induced
excitation of hypothalamic neurones is mediated by ATP-
sensitive Kþ channels. Pflugers Arch 415: 479–483, 1990.
8. Beckman JS, Beckman TW, Chen J, Marshall PA, and Free-
man BA. Apparent hydroxyl radical production by perox-
ynitrite: implications for endothelial injury from nitric oxide
and superoxide. Proc Natl Acad Sci USA 87: 1620–1624, 1990.
9. Bolanos JP and Almeida A. Modulation of astroglial energy
metabolism by nitric oxide. Antioxid Redox Signal 8: 955–965,
2006.
10 FIORAMONTI ET AL.
10. Bolanos JP, Almeida A, and Moncada S. Glycolysis: a bio-
energetic or a survival pathway? Trends Biochem Sci 35: 145–
149, 2009.
11. Borg MA, Sherwin RS, Borg WP, Tamborlane WV, and
Shulman GI. Local ventromedial hypothalamus glucose
perfusion blocks counterregulation during systemic hypo-
glycemia in awake rats. J Clin Invest 99: 361–365, 1997.
12. Borg MA, Tamborlane WV, Shulman GI, and Sherwin RS.
Local lactate perfusion of the ventromedial hypothalamus
suppresses hypoglycemic counterregulation. Diabetes 52:
663–666, 2003.
13. Borg WP, During MJ, Sherwin RS, Borg MA, Brines ML, and
Shulman GI. Ventromedial hypothalamic lesions in rats
suppress counterregulatory responses to hypoglycemia. J
Clin Invest 93: 1677–1682, 1994.
14. Borg WP, Sherwin RS, During MJ, Borg MA, and Shulman
GI. Local ventromedial hypothalamus glucopenia triggers
counterregulatory hormone release.Diabetes 44: 180–184, 1995.
15. Burdakov D, Luckman SM, and Verkhratsky A. Glucose-
sensing neurons of the hypothalamus. Philos Trans R Soc
Lond B Biol Sci 360: 2227–2235, 2005.
16. Canabal DD, Song Z, Potian JG, Beuve A, McArdle JJ, and
Routh VH. Glucose, insulin, and leptin signaling pathways
modulate nitric oxide synthesis in glucose-inhibited neurons
in the ventromedial hypothalamus. Am J Physiol Regul Integr
Comp Physiol 292: R1418–R1428, 2007.
17. Cidad P, Almeida A, and Bolanos JP. Inhibition of
mitochondrial respiration by nitric oxide rapidly stimulates
cytoprotective GLUT3-mediated glucose uptake through
50-AMP-activated protein kinase. Biochem J 384: 629–636, 2004.
18. Cooper CE. Competitive, reversible, physiological? Inhibi-
tion of mitochondrial cytochrome oxidase by nitric oxide.
IUBMB Life 55: 591–597, 2003.
19. Cooper CE, Davies NA, Psychoulis M, Canevari L, Bates TE,
Dobbie MS, Casley CS, and Sharpe MA. Nitric oxide and
peroxynitrite cause irreversible increases in the K(m) for
oxygen of mitochondrial cytochrome oxidase: in vitro and in
vivo studies. Biochim Biophys Acta 1607: 27–34, 2003.
20. Cotero VE and Routh VH. Insulin blunts the response of
glucose-excited neurons in the ventrolateral-ventromedial
hypothalamic nucleus to decreased glucose. Am J Physiol
Endocrinol Metab 296: E1101–E1109, 2009.
21. Cotero VE, Zhang BB, and Routh VH. The response of
glucose-excited (GE) neurons in the ventromedial hypo-
thalamus (VMH) to decreased glucose is enhanced in a
murine model of type 2 diabetes mellitus (T2DM). J Neu-
roendocrinol 22: 65–74, 2010.
22. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes
57: 3169–3176, 2008.
23. de Vries MG, Arseneau LM, Lawson ME, and Beverly JL.
Extracellular glucose in rat ventromedial hypothalamus
during acute and recurrent hypoglycemia. Diabetes 52: 2767–
2773, 2003.
24. DeFalco J, Tomishima M, Liu H, Zhao C, Cai X, Marth JD,
Enquist L, and Friedman JM. Virus-assisted mapping of
neural inputs to a feeding center in the hypothalamus. Sci-
ence 291: 2608–2613, 2001.
25. Dunn-Meynell AA, Rawson NE, and Levin BE. Distribution
and phenotype of neurons containing the ATP-sensitive Kþ
channel in rat brain. Brain Res 814: 41–54, 1998.
26. Dunn-Meynell AA, Routh VH, Kang L, Gaspers L, and Le-
vin BE. Glucokinase is the likely mediator of glucosensing in
both glucose- excited and glucose-inhibited central neurons.
Diabetes 51: 2056–2065, 2002.
27. Dunn-Meynell AA, Routh VH, McArdle JJ, and Levin BE.
Low-affinity sulfonylurea binding sites reside on neuronal
cell bodies in the brain. Brain Res 745: 1–9, 1997.
28. El Messari S, Leloup C, Quignon M, Brisorgueil MJ, Peni-
caud L, and Arluison M. Immunocytochemical localization
of the insulin-responsive glucose transporter 4 (Glut4) in
the rat central nervous system. J Comp Neurol 399: 492–512,
1998.
29. Evans ML, McCrimmon RJ, Flanagan DE, Keshavarz T, Fan
X, McNay EC, Jacob RJ, and Sherwin RS. Hypothalamic
ATP-sensitive Kþ channels play a key role in sensing hy-
poglycemia and triggering counterregulatory epinephrine
and glucagon responses. Diabetes 53: 2542–2551, 2004.
30. Fioramonti X, Contie S, Song Z, Routh VH, Lorsignol A, and
Penicaud L. Characterization of glucosensing neuron sub-
populations in the arcuate nucleus: integration in neuro-
peptide Y and pro-opio melanocortin networks? Diabetes 56:
1219–1227, 2007.
31. Fioramonti X, Lorsignol A, Taupignon A, and Penicaud L. A
new ATP-sensitive Kþ channel-independent mechanism is
involved in glucose-excited neurons of mouse arcuate nu-
cleus. Diabetes 53: 2767–2775, 2004.
32. Fioramonti X, Marsollier N, Song Z, Fakira KA, Patel RM,
Brown S, Duparc T, Pica-Mendez A, Sanders NM, Knauf C,
Valet P, McCrimmon RJ, Beuve A,Magnan C, and Routh VH.
Ventromedial hypothalamic nitric oxide production is nec-
essary for hypoglycemia detection and counterregulation.
Diabetes 59: 519–528, 2010.
33. Furuyama T, Inagaki S, and Takagi H. Localizations of alpha
1 and beta 1 subunits of soluble guanylate cyclase in the rat
brain. Brain Res Mol Brain Res 20: 335–344, 1993.
34. Han SM, Namkoong C, Jang PG, Park IS, Hong SW, Kata-
kami H, Chun S, Kim SW, Park JY, Lee KU, and Kim MS.
Hypothalamic AMP-activated protein kinase mediates
counter-regulatory responses to hypoglycaemia in rats.
Diabetologia 48: 2170–2178, 2005.
35. Herzog RI, Chan O, Yu S, Dziura J, McNay EC, and Sherwin
RS. Effect of acute and recurrent hypoglycemia on changes in
brain glycogen concentration. Endocrinology 149: 1499–1504, 2008.
36. Hess DT, Matsumoto A, Kim SO, Marshall HE, and Stamler
JS. Protein S-nitrosylation: purview and parameters. Nat Rev
Mol Cell Biol 6: 150–166, 2005.
37. Horinaka N, Artz N, Jehle J, Takahashi S, Kennedy C, and
Sokoloff L. Examination of potential mechanisms in the en-
hancement of cerebral blood flow by hypoglycemia and
pharmacological doses of deoxyglucose. J Cereb Blood Flow
Metab 17: 54–63, 1997.
38. Ischiropoulos H. Protein tyrosine nitration—an update. Arch
Biochem Biophys 484: 117–121, 2009.
39. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, and
Snyder SH. Protein S-nitrosylation: a physiological signal for
neuronal nitric oxide. Nat Cell Biol 3: 193–197, 2001.
40. Kang L, Dunn-Meynell AA, Routh VH, Gaspers LD, Nagata
Y, Nishimura T, Eiki J, Zhang BB, and Levin BE. Glucokinase
is a critical regulator of ventromedial hypothalamic neuronal
glucosensing. Diabetes 55: 412–420, 2006.
41. Kang L, Routh VH, Kuzhikandathil EV, Gaspers LD, and
Levin BE. Physiological and molecular characteristics of rat
hypothalamic ventromedial nucleus glucosensing neurons.
Diabetes 53: 549–559, 2004.
42. Kennan RP, Takahashi K, Pan C, Shamoon H, and Pan JW.
Human cerebral blood flow and metabolism in acute insulin-
induced hypoglycemia. J Cereb Blood Flow Metab 25: 527–534,
2005.
VMH NO PRODUCTION AND HYPOGLYCEMIA COUNTERREGULATION 11
43. Levin BE, Becker TC, Eiki J, Zhang BB, and Dunn-Meynell
AA. Ventromedial hypothalamic glucokinase is an impor-
tant mediator of the counterregulatory response to insulin-
induced hypoglycemia. Diabetes 57: 1371–1379, 2008.
44. Lira VA, Soltow QA, Long JH, Betters JL, Sellman JE, and
Criswell DS. Nitric oxide increases GLUT4 expression and
regulates AMPK signaling in skeletal muscle. Am J Physiol
Endocrinol Metab 293: E1062–E1068, 2007.
45. Magistretti PJ and Pellerin L. Astrocytes couple synaptic
activity to glucose utilization in the brain. News Physiol Sci
14: 177–182, 1999.
46. McCrimmon R. The mechanisms that underlie glucose
sensing during hypoglycaemia in diabetes. Diabet Med 25:
513–522, 2008.
47. McCrimmon RJ, Evans ML, Fan X, McNay EC, Chan O,
Ding Y, Zhu W, Gram DX, and Sherwin RS. Activation of
ATP-sensitive Kþ channels in the ventromedial hypothala-
mus amplifies counterregulatory hormone responses to hy-
poglycemia in normal and recurrently hypoglycemic rats.
Diabetes 54: 3169–3174, 2005.
48. McCrimmon RJ, Fan X, Cheng H, McNay E, Chan O, Shaw
M, Ding Y, Zhu W, and Sherwin RS. Activation of AMP-
activated protein kinase within the ventromedial hypothal-
amus amplifies counterregulatory hormone responses in rats
with defective counterregulation. Diabetes 55: 1755–1760,
2006.
49. McCrimmon RJ, Fan X, Ding Y, Zhu W, Jacob RJ, and
Sherwin RS. Potential role for AMP-activated protein kinase
in hypoglycemia sensing in the ventromedial hypothalamus.
Diabetes 53: 1953–1958, 2004.
50. McCrimmon RJ, Shaw M, Fan X, Cheng H, Ding Y, Vella
MC, Zhou L, McNay EC, and Sherwin RS. Key role for
AMP-activated protein kinase in the ventromedial hy-
pothalamus in regulating counterregulatory hormone re-
sponses to acute hypoglycemia. Diabetes 57: 444–450, 2008.
51. McCrimmon RJ, Song Z, Cheng H, McNay EC, Weikart-
Yeckel C, Fan X, Routh VH, and Sherwin RS. Cortico-
trophin-releasing factor receptors within the ventromedial
hypothalamus regulate hypoglycemia-induced hormonal
counterregulation. J Clin Invest 116: 1723–1730, 2006.
52. Miki T, Liss B, Minami K, Shiuchi T, Saraya A, Kashima Y,
Horiuchi M, Ashcroft F, Minokoshi Y, Roeper J, and Seino S.
ATP-sensitive Kþ channels in the hypothalamus are essen-
tial for the maintenance of glucose homeostasis. Nat Neurosci
4: 507–512, 2001.
53. Moncada S, Palmer RM, and Higgs EA. Nitric oxide: phys-
iology, pathophysiology, and pharmacology. Pharmacol Rev
43: 109–142, 1991.
54. Mountjoy PD, Bailey SJ, and Rutter GA. Inhibition by glu-
cose or leptin of hypothalamic neurons expressing neuro-
peptide Y requires changes in AMP-activated protein kinase
activity. Diabetologia 50: 168–177, 2007.
55. Mulberg AE, Weidner EB, Bao X, Marshall J, Jefferson DM,
and Altschuler SM. Cystic fibrosis transmembrane conduc-
tance regulator protein expression in brain. Neuroreport 5:
1684–1688, 1994.
56. Murphy BA, Fakira KA, Song Z, Beuve A, and Routh VH.
AMP-activated protein kinase and nitric oxide regulate the
glucose sensitivity of ventromedial hypothalamic glucose-
inhibited neurons. Am J Physiol Cell Physiol 297: C750–C758,
2009.
57. Oomura Y, Ono H, Ooyama H, and Wayner MJ. Glucose
and osmosensitive neurons of the rat hypothalamus. Nature
222: 282–284, 1969.
58. Page KA, Arora J, Qiu M, Relwani R, Constable RT, and
Sherwin RS. Small decrements in systemic glucose provoke
increases in hypothalamic blood flow prior to the release of
counterregulatory hormones. Diabetes 58: 448–452, 2009.
59. Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C,
Martin JL, Stella N, and Magistretti PJ. Evidence supporting
the existence of an activity-dependent astrocyte-neuron lac-
tate shuttle. Dev Neurosci 20: 291–299, 1998.
60. Riordan JR. Assembly of functional CFTR chloride channels.
Annu Rev Physiol 67: 701–718, 2005.
61. Rizzo MA and Piston DW. Regulation of beta cell glucoki-
nase by S-nitrosylation and association with nitric oxide
synthase. J Cell Biol 161: 243–248, 2003.
62. Routh V, McArdle JJ, Sanders NM, Wang R, and Song Z.
Glucose Sensing Neurons. Heilderburg: Springer, 2007.
63. Routh VH. Glucose-sensing neurons: are they physiologi-
cally relevant? Physiol Behav 76: 403–413, 2002.
64. Saberi M, Bohland M, and Donovan CM. The locus for hy-
poglycemic detection shifts with the rate of fall in glycemia:
the role of portal-superior mesenteric vein glucose sensing.
Diabetes 57: 1380–1386, 2008.
65. Sayed N, Baskaran P, Ma X, van den Akker F, and Beuve A.
Desensitization of soluble guanylyl cyclase, the NO receptor,
by S-nitrosylation. Proc Natl Acad Sci USA 104: 12312–12317,
2007.
66. Schwartz MW, Woods SC, Porte D Jr., Seeley RJ, and Baskin
DG. Central nervous system control of food intake. Nature
404: 661–671, 2000.
67. Singh P, Jain A, and Kaur G. Impact of hypoglycemia and
diabetes on CNS: correlation of mitochondrial oxidative
stress with DNA damage. Mol Cell Biochem 260: 153–159,
2004.
68. Song Z, Levin BE, McArdle JJ, Bakhos N, and Routh VH.
Convergence of pre- and postsynaptic influences on gluco-
sensing neurons in the ventromedial hypothalamic nucleus.
Diabetes 50: 2673–2681, 2001.
69. Song Z and Routh VH. Differential effects of glucose and
lactate on glucosensing neurons in the ventromedial hypo-
thalamic nucleus. Diabetes 54: 15–22, 2005.
70. Song Z and Routh VH. Recurrent hypoglycemia reduces the
glucose sensitivity of glucose-inhibited neurons in the ven-
tromedial hypothalamus nucleus. Am J Physiol Regul Integr
Comp Physiol 291: R1283–R1287, 2006.
71. Stamler JS, Toone EJ, Lipton SA, and Sucher NJ. (S)NO
signals: translocation, regulation, and a consensus motif.
Neuron 18: 691–696, 1997.
72. Stoddard-Apter SL, Bergdall VK, Townsend DW, and Levin
BE. Plasma catecholamines associated with hypothalami-
cally-elicited defense behavior. Physiol Behav 36: 867–873,
1986.
73. Tkacs NC, Dunn-Meynell AA, and Levin BE. Presumed
apoptosis and reduced arcuate nucleus neuropeptide Y and
pro-opiomelanocortin mRNA in non-coma hypoglycemia.
Diabetes 49: 820–826, 2000.
74. Vannucci RC and Vannucci SJ. Hypoglycemic brain injury.
Semin Neonatol 6: 147–155, 2001.
75. Vannucci SJ. Developmental expression of GLUT1 and
GLUT3 glucose transporters in rat brain. J Neurochem 62:
240–246, 1994.
76. Wang R, Liu X, Hentges ST, Dunn-Meynell AA, Levin BE,
Wang W, and Routh VH. The regulation of glucose-
excited neurons in the hypothalamic arcuate nucleus
by glucose and feeding-relevant peptides. Diabetes 53:
1959–1965, 2004.
12 FIORAMONTI ET AL.
77. Watts AG and Donovan CM. Sweet talk in the brain: Glu-
cosensing, neural networks, and hypoglycemic counter-
regulation. Front Neuroendocrinol 31: 32–43, 2010.
78. Yu HM, Xu J, Li C, Zhou C, Zhang F, Han D, and Zhang GY.
Coupling between neuronal nitric oxide synthase and glu-
tamate receptor 6-mediated c-Jun N-terminal kinase signal-
ing pathway via S-nitrosylation contributes to ischemia
neuronal death. Neuroscience 155: 1120–1132, 2008.
79. Zeitlin PL. Is it go or NO go for S-nitrosylation modification-
based therapies of cystic fibrosis transmembrane regulator
trafficking? Mol Pharmacol 70: 1155–1158, 2006.
80. Zhang J, Xie Z, Dong Y, Wang S, Liu C, and Zou MH.
Identification of nitric oxide as an endogenous activator of
the AMP-activated protein kinase in vascular endothelial
cells. J Biol Chem 283: 27452–27461, 2008.
Address correspondence to:
Dr. Xavier Fioramonti
Department of Pharmacology and Physiology
New Jersey Medical School
P.O. Box 1709
Newark, NJ 07101-1709
E-mail: fioramxa@umdnj.edu
Date of first submission to ARS Central, May 26, 2010; date of
acceptance, June 2, 2010.
Abbreviations Used
AMPK¼AMP-activated kinase
APF¼ action potential frequency
ARC¼ arcuate nucleus
CFTR¼ cystic fibrosis transmembrane regulator
cGMP¼ cyclic guanosine monophosphate
CRR¼ counterregulatory response
eNOS¼ endothelial NOS
GE¼ glucose-excited
GI¼ glucose-inhibited
GK¼ glucokinase
GLUT¼ glucose transporter
GSNs¼ glucose-sensing neurons
HAAF¼hypoglycemia-associated
autonomic failure
KATP¼ATP-sensitive potassium channel
MCT¼monocarboxylate transporter
nNOS¼neuronal NOS
NO¼nitric oxide
NOS¼NO synthase
NPY¼neuropeptide Y
RH¼ recurrent hypoglycemia
ROS¼ reactive oxygen species
sGC¼ soluble guanylate cyclase
T1DM¼ type 1 diabetes mellitus
VMH¼ventromedial hypothalamus
VMN¼ventromedial nucleus
VMH NO PRODUCTION AND HYPOGLYCEMIA COUNTERREGULATION 13

